Alternative splicing in the genome of HPV and its regulation

Yaping Wang, Fang Chen, Wenjie Qu, Yingxin Gong, Yan Wang, Limei Chen, Qi Zhou, Jiayin Mo, Hongwei Zhang, Lin Lin, Tianyi Bi, Xujie Wang, Jiashi Gu, Yanyun Li, Long SuiFrontiers in Cellular and Infection Microbiology 2024 · DOI

Abstract

Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary driver of cervical cancer. These infections are characterized by the high expression of E6 and E7 oncogenes and the absence of capsid proteins. A critical challenge for HPV is its compact 8kb genome, which must encode multiple proteins from polycistronic transcripts. Alternative splicing serves as a vital post-transcriptional mechanism to diversify the viral proteome. This review synthesizes current knowledge on HPV alternative splicing, focusing on the regulatory interplay between host factors and viral proteins, and the functional roles of various splice isoforms in cancer progression.

The Genomic Bottleneck: Why Splicing Matters

Human Papillomavirus (HPV) possesses a remarkably compact double-stranded DNA genome of approximately 8,000 base pairs. Despite its small size, the virus must produce a diverse array of proteins to manage its complex life cycle and, in high-risk types, drive oncogenic transformation.

The primary challenge lies in the polycistronic nature of its mRNAs—a single transcript often contains multiple Open Reading Frames (ORFs). Because eukaryotic ribosomes typically only translate the first ORF they encounter, downstream genes would remain silent without intervention. HPV overcomes this "bottleneck" through alternative splicing, which physically repositions downstream ORFs closer to the 5’ end of the mRNA, enabling their expression.

Transcription map of the HPV genome showing the diversity of splice isoforms generated from a compact set of ORFs.

Mechanisms and Regulation of Alternative Splicing

The diversity of HPV transcripts is achieved through the use of multiple promoters (e.g., p97, p670, pE8) and alternative splice sites. As shown in the transcription map above, a single primary transcript can be processed into numerous isoforms, such as the E6* variants, E1^E4, and E8^E2.

Splicing is governed by a delicate balance between host cell machinery and viral feedback:

  • Host Factors: Splicing is regulated by the tug-of-war between host SR proteins (which generally promote splicing) and hnRNPs (which often inhibit it). For instance, hnRNP A1 and A2 act as silencers to prevent the premature expression of late capsid proteins (L1/L2), helping the virus evade the host immune system during early infection.
  • Viral Master Regulators: The viral E2 protein acts as a master regulator. High levels of E2 can modulate host splicing factors like SRSF3, effectively controlling the "switch" from early viral replication to the production of late-stage viral particles.
  • High-Risk vs. Low-Risk Divergence: A major structural difference between high-risk (HR-HPV) and low-risk (LR-HPV) genotypes is the presence of an intron within the E6 ORF. LR-HPVs (like types 6 and 11) lack this intron and cannot produce E6* isoforms, a factor likely contributing to their lower oncogenic potential.

Functional Roles of Splice Isoforms

The resulting protein isoforms play distinct roles in the viral life cycle and cancer development:

  • The E6* "Enabler": E6*I is one of the most studied isoforms. While it is a truncated version of the E6 oncogene, its primary function appears to be facilitating the translation of the E7 oncogene by splicing out the E6 intron, allowing the ribosome to reach the E7 start codon more efficiently.
  • Tumorigenic Roles: Beyond E6*I, which can increase reactive oxygen species (ROS) and activate Wnt signaling, other isoforms like E8^E2 contribute to immune escape.
  • Late Stage Functions: Isoforms like E1^E4 induce cell cycle arrest, favoring the eventual release of new viral particles.

Future Directions and Clinical Implications

While significant progress has been made in mapping the HPV "interactome," several gaps remain. Research is heavily biased toward HPV16 and HPV18, leaving other high-risk types understudied. Furthermore, the upstream signaling pathways (such as the EGF/Erk1/2 pathway) that trigger changes in splicing behavior during infection are not fully understood.

Understanding these mechanisms offers promising avenues for clinical application. Splicing factors could serve as therapeutic targets to disrupt the viral life cycle. Additionally, specific splice isoforms may eventually be utilized as reliable biomarkers for the early diagnosis and risk stratification of cervical lesions.

Summary updated

Abstract

Persistent infection with high-risk human papillomavirus (HR-HPV) is the main cause of cervical cancer. These chronic infections are characterized by high expression of the HPV E6 and E7 oncogenes and the absence of the L1 and L2 capsid proteins. The regulation of HPV gene expression plays a crucial role in both the viral life cycle and rare oncogenic events. Alternative splicing of HPV mRNA is a key mechanism in post-transcriptional regulation. Through alternative splicing, HPV mRNA is diversified into various splice isoforms with distinct coding potentials, encoding multiple proteins and influencing the expression of HPV genes. The spliced mRNAs derived from a donor splicing site within the E6 ORF and one of the different acceptor sites located in the early mRNA contain E6 truncated mRNAs, named E6*. E6* is one of the extensively studied splicing isoforms. However, the role of E6* proteins in cancer progression remains controversial. Here, we reviewed and compared the alternative splicing events occurring in the genomes of HR-HPV and LR-HPV. Recently, new HPV alternative splicing regulatory proteins have been continuously discovered, and we have updated the regulation of HPV alternative splicing. In addition, we summarized the functions of known splice isoforms from three aspects: anti-tumorigenic, tumorigenic, and other cancer-related functions, including not only E6*, but also E6^E7, E8^E2, and so on. Comprehending their contributions to cancer development enhances insights into the carcinogenic mechanisms of HPV and explores the potential utility of alternative splicing in the diagnosis and treatment of cervical cancer.
BibTeX
@inproceedings{wang2024alternative,
  author = {Yaping Wang and Fang Chen and Wenjie Qu and Yingxin Gong and Yan Wang and Limei Chen and Qi Zhou and Jiayin Mo and Hongwei Zhang and Lin Lin and Tianyi Bi and Xujie Wang and Jiashi Gu and Yanyun Li and Long Sui},
  title = {{Alternative splicing in the genome of HPV and its regulation}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1443868},
}
Figure